Alfonso De Stefano
@adestefano.bsky.social
MD, PhD. GI Medical Oncologist - Experimental Clinical Abdominal Oncology Unit, Istituto Nazionale Tumori - IRCCS -Fondazione G. Pascale, Napoli, Italy #ESMO #ISLB member #OncSky #GIonc
Pinned
#IMPROVE trial #Intermittent (I) or #Continuous (C) Panitumumab+FOLFIRI for First-Line Treatment of RAS/BRAF WT Metastatic Colorectal Cancer #oncsky #JCO
✅ Endpoint met
👉mPFS 11.2(C)vs17.5 months(I)
👉NO detrimental effect on OS
👉DCR 94.2%(C)vs91%(I)
👉Reduced toxicity
ascopubs.org/doi/pdf/10.1...
✅ Endpoint met
👉mPFS 11.2(C)vs17.5 months(I)
👉NO detrimental effect on OS
👉DCR 94.2%(C)vs91%(I)
👉Reduced toxicity
ascopubs.org/doi/pdf/10.1...
Confirmed great data from #8HW trial at #ESMO25 with the combination NIVO+IPI confirms the standard of care option in 1st line MSI-H/dMMR mCRC patients @oncodaily.bsky.social
October 20, 2025 at 7:11 AM
Confirmed great data from #8HW trial at #ESMO25 with the combination NIVO+IPI confirms the standard of care option in 1st line MSI-H/dMMR mCRC patients @oncodaily.bsky.social
Thanks 🙏🏻 to @oncodaily.bsky.social to highlight the results of #IMPROVE trial Intermittent or Continuous FOLFIRI + Panitumumab RAS and BRAF Wild-Type Metastatic #CRC #GIonc #OncSky oncodaily.com/blog/panitum...
Intermittent or Continuous FOLFIRI + Panitumumab RAS and BRAF Wild-Type Metastatic CRC - OncoDaily
Intermittent or Continuous FOLFIRI + Panitumumab RAS and BRAF Wild-Type Metastatic CRC / Akhil Santhosh, Alberto Sobrero, Alessandra Leone, Alfonso De
oncodaily.com
January 18, 2025 at 10:11 PM
Thanks 🙏🏻 to @oncodaily.bsky.social to highlight the results of #IMPROVE trial Intermittent or Continuous FOLFIRI + Panitumumab RAS and BRAF Wild-Type Metastatic #CRC #GIonc #OncSky oncodaily.com/blog/panitum...
Reposted by Alfonso De Stefano
Exciting #GIonc INFINITY ♾ #Ph2 trial
Neoadjuvant #IO in #stcsm #esocsm using #treme + #durva ~60% pCR
12m 🚫🔪#survival ~ 64%.
#Ph3 data needed, but organ preservation possible!
🔗: sciencedirect.com/science/arti...
Neoadjuvant #IO in #stcsm #esocsm using #treme + #durva ~60% pCR
12m 🚫🔪#survival ~ 64%.
#Ph3 data needed, but organ preservation possible!
🔗: sciencedirect.com/science/arti...
Tremelimumab and durvalumab as neoadjuvant or non-operative management strategy of patients with microsatellite instability-high resectable gastric or gastroesophageal junction adenocarcinoma: the INF...
In resectable gastric/gastroesophageal junction adenocarcinoma, microsatellite instability-high (MSI-H) confers improved survival, but limited benefit…
sciencedirect.com
January 16, 2025 at 7:59 PM
Reposted by Alfonso De Stefano
#GI25 @ascocancer.bsky.social
For #colorectalcancer, there are many great abstracts-so this is just a few to🔦:
Pre-op:
1⃣@CQvortrup🗣️a Single-cycle of neoadj pembro for Stage I-III MMRdef CRC, Oral Abs 19
2⃣@jonathanloree🗣️using ctDNA🩸to support Non-Op management in rectal cancer, Oral Abs 20
For #colorectalcancer, there are many great abstracts-so this is just a few to🔦:
Pre-op:
1⃣@CQvortrup🗣️a Single-cycle of neoadj pembro for Stage I-III MMRdef CRC, Oral Abs 19
2⃣@jonathanloree🗣️using ctDNA🩸to support Non-Op management in rectal cancer, Oral Abs 20
January 11, 2025 at 7:57 PM
#GI25 @ascocancer.bsky.social
For #colorectalcancer, there are many great abstracts-so this is just a few to🔦:
Pre-op:
1⃣@CQvortrup🗣️a Single-cycle of neoadj pembro for Stage I-III MMRdef CRC, Oral Abs 19
2⃣@jonathanloree🗣️using ctDNA🩸to support Non-Op management in rectal cancer, Oral Abs 20
For #colorectalcancer, there are many great abstracts-so this is just a few to🔦:
Pre-op:
1⃣@CQvortrup🗣️a Single-cycle of neoadj pembro for Stage I-III MMRdef CRC, Oral Abs 19
2⃣@jonathanloree🗣️using ctDNA🩸to support Non-Op management in rectal cancer, Oral Abs 20
Reposted by Alfonso De Stefano
#GI25 @ascocancer.bsky.social
The BIG trial in #colorectalcancer will be Scott Kopetz 🗣️BREAKWATER, the 1st line R-Ph3 trial of encorafenib + cetuximab + chemotherapy in BRAF V600E-mutant met CRC, Oral Abs 16
The BIG trial in #colorectalcancer will be Scott Kopetz 🗣️BREAKWATER, the 1st line R-Ph3 trial of encorafenib + cetuximab + chemotherapy in BRAF V600E-mutant met CRC, Oral Abs 16
January 11, 2025 at 7:57 PM
#GI25 @ascocancer.bsky.social
The BIG trial in #colorectalcancer will be Scott Kopetz 🗣️BREAKWATER, the 1st line R-Ph3 trial of encorafenib + cetuximab + chemotherapy in BRAF V600E-mutant met CRC, Oral Abs 16
The BIG trial in #colorectalcancer will be Scott Kopetz 🗣️BREAKWATER, the 1st line R-Ph3 trial of encorafenib + cetuximab + chemotherapy in BRAF V600E-mutant met CRC, Oral Abs 16
Reposted by Alfonso De Stefano
#GI25 @ascocancer.bsky.social
And 3 immunotherapy trials in #MCRC:
1⃣Thierry Andre🗣️the LBA of Ipi-Nivo vs Nivo of dMMR mCRC, ABS LBA143
2⃣ Marwan Fakih🗣️a Ph2 trial of BOT +/- Bal in MSS mCRC (no liver mets), Oral Abs 23
3⃣Joel R Hecht🗣️a Ph2 trial of a personalized Neo-Ant IO for MSS CRC, Abs LBA13
And 3 immunotherapy trials in #MCRC:
1⃣Thierry Andre🗣️the LBA of Ipi-Nivo vs Nivo of dMMR mCRC, ABS LBA143
2⃣ Marwan Fakih🗣️a Ph2 trial of BOT +/- Bal in MSS mCRC (no liver mets), Oral Abs 23
3⃣Joel R Hecht🗣️a Ph2 trial of a personalized Neo-Ant IO for MSS CRC, Abs LBA13
January 11, 2025 at 7:57 PM
#GI25 @ascocancer.bsky.social
And 3 immunotherapy trials in #MCRC:
1⃣Thierry Andre🗣️the LBA of Ipi-Nivo vs Nivo of dMMR mCRC, ABS LBA143
2⃣ Marwan Fakih🗣️a Ph2 trial of BOT +/- Bal in MSS mCRC (no liver mets), Oral Abs 23
3⃣Joel R Hecht🗣️a Ph2 trial of a personalized Neo-Ant IO for MSS CRC, Abs LBA13
And 3 immunotherapy trials in #MCRC:
1⃣Thierry Andre🗣️the LBA of Ipi-Nivo vs Nivo of dMMR mCRC, ABS LBA143
2⃣ Marwan Fakih🗣️a Ph2 trial of BOT +/- Bal in MSS mCRC (no liver mets), Oral Abs 23
3⃣Joel R Hecht🗣️a Ph2 trial of a personalized Neo-Ant IO for MSS CRC, Abs LBA13
Reposted by Alfonso De Stefano
#GIonc summary
top 3 trials in #crcsm
🥇: NICHE-2 - 99% #ORR, 100% 3-year DFS in dMMR colon cancer with ⬇️ #tox
🥈: KRYSTAL-1 - adagrasib in KRAS G12C cancers ➡️ FDA approval + cetux
🥉: TransMet - transplant + 💉 improves 5y #OS
🔗: nature.com/articles/s41...
top 3 trials in #crcsm
🥇: NICHE-2 - 99% #ORR, 100% 3-year DFS in dMMR colon cancer with ⬇️ #tox
🥈: KRYSTAL-1 - adagrasib in KRAS G12C cancers ➡️ FDA approval + cetux
🥉: TransMet - transplant + 💉 improves 5y #OS
🔗: nature.com/articles/s41...
Moving towards more personalized approaches in locally advanced and metastatic colorectal cancer - Nature Reviews Gastroenterology & Hepatology
Colorectal cancer remains a challenging heterogeneous disease with substantial morbidity and mortality. However, progressive advances over the past year have led to marked improvements and overcome ch...
nature.com
January 14, 2025 at 8:34 PM
Neo-adjuvantFOLFOX+/- #panitumumab for pts with KRAS-wt locally advanced #coloncancer: FOxTROT Trial www.annalsofoncology.org/article/S092... ➡️ @jenseligmann.bsky.social #GIonc @oncoalert.bsky.social
👉⬇️recurrence 12% vs 21%(HR=0.51,p0.09),significant in EREG/AREG ⬆️
👉⬆️TOX G3 diarrhoea and rash
👉⬇️recurrence 12% vs 21%(HR=0.51,p0.09),significant in EREG/AREG ⬆️
👉⬆️TOX G3 diarrhoea and rash
January 12, 2025 at 4:08 PM
Neo-adjuvantFOLFOX+/- #panitumumab for pts with KRAS-wt locally advanced #coloncancer: FOxTROT Trial www.annalsofoncology.org/article/S092... ➡️ @jenseligmann.bsky.social #GIonc @oncoalert.bsky.social
👉⬇️recurrence 12% vs 21%(HR=0.51,p0.09),significant in EREG/AREG ⬆️
👉⬆️TOX G3 diarrhoea and rash
👉⬇️recurrence 12% vs 21%(HR=0.51,p0.09),significant in EREG/AREG ⬆️
👉⬆️TOX G3 diarrhoea and rash
PD-1 blockade with Tislelizumab+chemoradiotherapy in unselected MMR locally advanced #rectalcancer
doi.org/10.1038/s415... @natmedicine.bsky.social
✅The pCR rates were 27.1%, 32.7% and 14.0% for experiment groups A and B and the control group C, respectively
doi.org/10.1038/s415... @natmedicine.bsky.social
✅The pCR rates were 27.1%, 32.7% and 14.0% for experiment groups A and B and the control group C, respectively
January 12, 2025 at 7:55 AM
PD-1 blockade with Tislelizumab+chemoradiotherapy in unselected MMR locally advanced #rectalcancer
doi.org/10.1038/s415... @natmedicine.bsky.social
✅The pCR rates were 27.1%, 32.7% and 14.0% for experiment groups A and B and the control group C, respectively
doi.org/10.1038/s415... @natmedicine.bsky.social
✅The pCR rates were 27.1%, 32.7% and 14.0% for experiment groups A and B and the control group C, respectively
Reposted by Alfonso De Stefano
Cystatin A promotes the antitumor activity of T helper type 1 cells and dendritic cells in murine models of pancreatic cancer 🧪 #PancreaticCancer febs.onlinelibrary.wiley.com/doi/10.1002/...
FEBS Press
Pancreatic ductal adenocarcinoma (PDAC) is a disease with very poor prognosis due to therapeutic limitations. We investigated the antitumor effects of cystatin A (CSTA) in PDAC murine models. We are ...
febs.onlinelibrary.wiley.com
January 11, 2025 at 7:32 PM
Cystatin A promotes the antitumor activity of T helper type 1 cells and dendritic cells in murine models of pancreatic cancer 🧪 #PancreaticCancer febs.onlinelibrary.wiley.com/doi/10.1002/...
Reposted by Alfonso De Stefano
#GI25 @ascocancer.bsky.social
Finally, two additional abstracts to watch for in #cholangiocarcinoma:
1⃣Dr. Priyanshi Shah🗣️Long-term outcomes for MSI-H BTC patients on immunotherapy, Abs 592; Post#C18
2⃣Dr. Christos Fountzilas🗣️🎯FGFR in the Ph2 trial of Tinengotinib for BTC Pts, Abs 608; Post#D9
Finally, two additional abstracts to watch for in #cholangiocarcinoma:
1⃣Dr. Priyanshi Shah🗣️Long-term outcomes for MSI-H BTC patients on immunotherapy, Abs 592; Post#C18
2⃣Dr. Christos Fountzilas🗣️🎯FGFR in the Ph2 trial of Tinengotinib for BTC Pts, Abs 608; Post#D9
January 11, 2025 at 7:33 PM
#GI25 @ascocancer.bsky.social
Finally, two additional abstracts to watch for in #cholangiocarcinoma:
1⃣Dr. Priyanshi Shah🗣️Long-term outcomes for MSI-H BTC patients on immunotherapy, Abs 592; Post#C18
2⃣Dr. Christos Fountzilas🗣️🎯FGFR in the Ph2 trial of Tinengotinib for BTC Pts, Abs 608; Post#D9
Finally, two additional abstracts to watch for in #cholangiocarcinoma:
1⃣Dr. Priyanshi Shah🗣️Long-term outcomes for MSI-H BTC patients on immunotherapy, Abs 592; Post#C18
2⃣Dr. Christos Fountzilas🗣️🎯FGFR in the Ph2 trial of Tinengotinib for BTC Pts, Abs 608; Post#D9
Reposted by Alfonso De Stefano
#GI25 @ascocancer.bsky.social
3⃣abstracts🔬outcomes of Pts with specific🧬alterations in #cholangiocarcinoma:
1⃣&2⃣look at MDM2amp BTC:
➡️Dr. Iyer, Abs 544; Post#A22
➡️Teresa Macarulla, Abs 615, Post#D16
3⃣Richard Kim🗣️Real-World OS in BTC Pts with IDH1mut or FGFR2fus + BTC, Abs 548; Post#A26
3⃣abstracts🔬outcomes of Pts with specific🧬alterations in #cholangiocarcinoma:
1⃣&2⃣look at MDM2amp BTC:
➡️Dr. Iyer, Abs 544; Post#A22
➡️Teresa Macarulla, Abs 615, Post#D16
3⃣Richard Kim🗣️Real-World OS in BTC Pts with IDH1mut or FGFR2fus + BTC, Abs 548; Post#A26
January 11, 2025 at 7:33 PM
#GI25 @ascocancer.bsky.social
3⃣abstracts🔬outcomes of Pts with specific🧬alterations in #cholangiocarcinoma:
1⃣&2⃣look at MDM2amp BTC:
➡️Dr. Iyer, Abs 544; Post#A22
➡️Teresa Macarulla, Abs 615, Post#D16
3⃣Richard Kim🗣️Real-World OS in BTC Pts with IDH1mut or FGFR2fus + BTC, Abs 548; Post#A26
3⃣abstracts🔬outcomes of Pts with specific🧬alterations in #cholangiocarcinoma:
1⃣&2⃣look at MDM2amp BTC:
➡️Dr. Iyer, Abs 544; Post#A22
➡️Teresa Macarulla, Abs 615, Post#D16
3⃣Richard Kim🗣️Real-World OS in BTC Pts with IDH1mut or FGFR2fus + BTC, Abs 548; Post#A26
Many thanks to @mpishvaian.bsky.social to share his top abstract titles of the upcoming #GI25 @ascocancer.bsky.social #GIonc
#GI25 @ascocancer.bsky.social
Starting with #PancreaticCancer and Ras⛔️
Actually only2⃣titles I saw:
1⃣Ignacio Garrido-Laguna🗣️ctDNA🩸changes in the Ph1 trial of the Ras(on)⛔️RMC-6236 Abs 722; Poster#H10
2⃣Alex Spira🗣️a Ph1 trial of the G12D specific⛔️RMC-9805 Abs 724; Poster#H12
Starting with #PancreaticCancer and Ras⛔️
Actually only2⃣titles I saw:
1⃣Ignacio Garrido-Laguna🗣️ctDNA🩸changes in the Ph1 trial of the Ras(on)⛔️RMC-6236 Abs 722; Poster#H10
2⃣Alex Spira🗣️a Ph1 trial of the G12D specific⛔️RMC-9805 Abs 724; Poster#H12
January 11, 2025 at 7:01 PM
Many thanks to @mpishvaian.bsky.social to share his top abstract titles of the upcoming #GI25 @ascocancer.bsky.social #GIonc
A-REPEAT trial: #panitumumab based #rechallenge strategy in pretteated metastatic #crc pts. The study was closed prematurely but highlights the importance of #LiquidBiopsy before rechallenge:48% of pts were RAS mutant #GIonc #OncSky @christianrolfo.bsky.social www.sciencedirect.com/science/arti...
Anti-EGFR re-challenge with chemotherapy in RAS wild-type advanced colorectal cancer (A-REPEAT study): efficacy and correlations with tissue and plasma genotyping
Approved treatments for colorectal cancer (CRC) patients pretreated with two lines of therapy are of limited efficacy. Anti-epidermal growth factor re…
www.sciencedirect.com
January 11, 2025 at 4:56 PM
A-REPEAT trial: #panitumumab based #rechallenge strategy in pretteated metastatic #crc pts. The study was closed prematurely but highlights the importance of #LiquidBiopsy before rechallenge:48% of pts were RAS mutant #GIonc #OncSky @christianrolfo.bsky.social www.sciencedirect.com/science/arti...
Reposted by Alfonso De Stefano
The OncoAlert🚨 Network along with our partners at
ESSO, ESGO, MASCC & SIOG
invite you to the #OncoAlertColloquium
REGISTER for FREE HERE👉 buff.ly/3CChgre
February 3-9, 2025 💯% Virtual & Interactive
@erikahamilton9.bsky.social
@drsgraff.bsky.social
@drjnaidoo.bsky.social
@hoperugo.bsky.social
ESSO, ESGO, MASCC & SIOG
invite you to the #OncoAlertColloquium
REGISTER for FREE HERE👉 buff.ly/3CChgre
February 3-9, 2025 💯% Virtual & Interactive
@erikahamilton9.bsky.social
@drsgraff.bsky.social
@drjnaidoo.bsky.social
@hoperugo.bsky.social
January 10, 2025 at 6:23 PM
The OncoAlert🚨 Network along with our partners at
ESSO, ESGO, MASCC & SIOG
invite you to the #OncoAlertColloquium
REGISTER for FREE HERE👉 buff.ly/3CChgre
February 3-9, 2025 💯% Virtual & Interactive
@erikahamilton9.bsky.social
@drsgraff.bsky.social
@drjnaidoo.bsky.social
@hoperugo.bsky.social
ESSO, ESGO, MASCC & SIOG
invite you to the #OncoAlertColloquium
REGISTER for FREE HERE👉 buff.ly/3CChgre
February 3-9, 2025 💯% Virtual & Interactive
@erikahamilton9.bsky.social
@drsgraff.bsky.social
@drjnaidoo.bsky.social
@hoperugo.bsky.social
Interesting review on advances in targeting 🎯#KRAS in #mCRC Development of KRAS Inhibitors and Their Role for Metastatic Colorectal Cancer
by Dr.Dustin Deming on #JNCCN
jnccn.org/view/journal... @oncoalert.bsky.social @oncodaily.bsky.social @medicalwatch.bsky.social
by Dr.Dustin Deming on #JNCCN
jnccn.org/view/journal... @oncoalert.bsky.social @oncodaily.bsky.social @medicalwatch.bsky.social
jnccn.org
January 6, 2025 at 8:39 PM
Interesting review on advances in targeting 🎯#KRAS in #mCRC Development of KRAS Inhibitors and Their Role for Metastatic Colorectal Cancer
by Dr.Dustin Deming on #JNCCN
jnccn.org/view/journal... @oncoalert.bsky.social @oncodaily.bsky.social @medicalwatch.bsky.social
by Dr.Dustin Deming on #JNCCN
jnccn.org/view/journal... @oncoalert.bsky.social @oncodaily.bsky.social @medicalwatch.bsky.social
Reposted by Alfonso De Stefano
www.nature.com/articles/d41...
The Landscape of @fda.gov drug approvals in 2024. 30% Oncology novel drugs !
The Landscape of @fda.gov drug approvals in 2024. 30% Oncology novel drugs !
2024 FDA approvals
The FDA approved 50 new therapeutics in 2024, with green lights for a novel schizophrenia drug, a first NASH medicine and much more.
www.nature.com
January 4, 2025 at 5:43 PM
www.nature.com/articles/d41...
The Landscape of @fda.gov drug approvals in 2024. 30% Oncology novel drugs !
The Landscape of @fda.gov drug approvals in 2024. 30% Oncology novel drugs !
Happy New Year to everyone! @oncodaily.bsky.social @oncoalert.bsky.social
@medicalwatch.bsky.social
@katesears.bsky.social
@medicalwatch.bsky.social
@katesears.bsky.social
January 1, 2025 at 12:10 AM
Happy New Year to everyone! @oncodaily.bsky.social @oncoalert.bsky.social
@medicalwatch.bsky.social
@katesears.bsky.social
@medicalwatch.bsky.social
@katesears.bsky.social
📢Very useful suggestions from @medicalwatch.bsky.social @katesears.bsky.social directly forwarded to your📁📬email. You can subscribe to get a monthly update on phase 3 interventional clinical trials recruiting near you on your field of interest. Congrats and thanks for this project!👏🏻💪🏻 #OncSky #GIonc
December 30, 2024 at 3:26 PM
📢Very useful suggestions from @medicalwatch.bsky.social @katesears.bsky.social directly forwarded to your📁📬email. You can subscribe to get a monthly update on phase 3 interventional clinical trials recruiting near you on your field of interest. Congrats and thanks for this project!👏🏻💪🏻 #OncSky #GIonc
Another issue on the role of #LiquidBiopsy in #CRC 👉 In these patients with stage II-IV CRC who underwent curative-intent resection,the benefit of adding serial tumor-informed ctDNA assay to the standard surveillance was limited #ISLB #GIonc @oncoalert.bsky.social
jamanetwork.com/journals/jam...
jamanetwork.com/journals/jam...
December 30, 2024 at 4:21 AM
Another issue on the role of #LiquidBiopsy in #CRC 👉 In these patients with stage II-IV CRC who underwent curative-intent resection,the benefit of adding serial tumor-informed ctDNA assay to the standard surveillance was limited #ISLB #GIonc @oncoalert.bsky.social
jamanetwork.com/journals/jam...
jamanetwork.com/journals/jam...
Reposted by Alfonso De Stefano
Dear Colleagues,
Wishing you hashtag#MerryChrismas2024 & Happy Holidays from All of us at OncoAlert 🚨
@elisaagostinetto.bsky.social
@drjnaidoo.bsky.social
@lymphomadoc.bsky.social
@realbowtiedoc.bsky.social
@stephenvliu.bsky.social
@drlestercoll.bsky.social
@erikahamilton9.bsky.social
Wishing you hashtag#MerryChrismas2024 & Happy Holidays from All of us at OncoAlert 🚨
@elisaagostinetto.bsky.social
@drjnaidoo.bsky.social
@lymphomadoc.bsky.social
@realbowtiedoc.bsky.social
@stephenvliu.bsky.social
@drlestercoll.bsky.social
@erikahamilton9.bsky.social
December 24, 2024 at 10:21 PM
Dear Colleagues,
Wishing you hashtag#MerryChrismas2024 & Happy Holidays from All of us at OncoAlert 🚨
@elisaagostinetto.bsky.social
@drjnaidoo.bsky.social
@lymphomadoc.bsky.social
@realbowtiedoc.bsky.social
@stephenvliu.bsky.social
@drlestercoll.bsky.social
@erikahamilton9.bsky.social
Wishing you hashtag#MerryChrismas2024 & Happy Holidays from All of us at OncoAlert 🚨
@elisaagostinetto.bsky.social
@drjnaidoo.bsky.social
@lymphomadoc.bsky.social
@realbowtiedoc.bsky.social
@stephenvliu.bsky.social
@drlestercoll.bsky.social
@erikahamilton9.bsky.social
Find the results in the open access paper on #JCO @ascocancer.bsky.social at ascopubs.org/doi/pdf/10.1... #OncSky #GIonc
December 24, 2024 at 8:35 AM
Find the results in the open access paper on #JCO @ascocancer.bsky.social at ascopubs.org/doi/pdf/10.1... #OncSky #GIonc
Find the results in the open access paper on #JCO @ascocancer.bsky.social at ascopubs.org/doi/pdf/10.1...
December 24, 2024 at 7:49 AM
Find the results in the open access paper on #JCO @ascocancer.bsky.social at ascopubs.org/doi/pdf/10.1...
🙏🏻 Grateful to @medicalwatch.bsky.social and @katesears.bsky.social to promote the results of IMPROVE trial ascopubs.org/doi/pdf/10.1... in the weekly newsletter! To be always updated on most recent trials, you can subscribe at my.medical.watch/signup
December 24, 2024 at 4:42 AM
🙏🏻 Grateful to @medicalwatch.bsky.social and @katesears.bsky.social to promote the results of IMPROVE trial ascopubs.org/doi/pdf/10.1... in the weekly newsletter! To be always updated on most recent trials, you can subscribe at my.medical.watch/signup
A very interesting course here in Italy, very recommended to all oncology researchers @ascocancer.bsky.social
ASCO – Applications are open for an interactive clinical research course with AIOM
@ascocancer.bsky.social
oncodaily.com/blog/asco-21...
#ASCO #Cancer #OncoDaily #Oncology #Medicine #Health
@ascocancer.bsky.social
oncodaily.com/blog/asco-21...
#ASCO #Cancer #OncoDaily #Oncology #Medicine #Health
ASCO - Applications are open for an interactive clinical research course with AIOM - OncoDaily
ASCO - Applications are open for an interactive clinical research course with AIOM / ASCO, cancer, OncoDaily, Oncology
oncodaily.com
December 22, 2024 at 5:57 PM
A very interesting course here in Italy, very recommended to all oncology researchers @ascocancer.bsky.social